Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Tiziana Life Sciences stock | $1.51

Learn how to easily invest in Tiziana Life Sciences stock.

Tiziana Life Sciences PLC is a biotechnology business based in the US. Tiziana Life Sciences shares (TLSA) are listed on the NASDAQ and all prices are listed in US Dollars. Tiziana Life Sciences employs 11 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Tiziana Life Sciences

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TLSA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Tiziana Life Sciences stock price (NASDAQ: TLSA)

Use our graph to track the performance of TLSA stocks over time.

Tiziana Life Sciences shares at a glance

Information last updated 2021-10-18.
Latest market close$1.51
52-week range$1.36 - $5.29
50-day moving average $1.62
200-day moving average $2.10
Wall St. target price$7.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.45

Buy Tiziana Life Sciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Tiziana Life Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Tiziana Life Sciences price performance over time

Historical closes compared with the close of $1.51 from 2021-10-22

1 week (2021-10-15) 1.51
1 month (2021-09-24) 1.51
3 months (2021-07-23) -27.05%
6 months (2021-04-23) -40.55%
1 year (2020-10-23) -65.84%
2 years (2019-10-23) -75.19%
3 years (2018-10-20) N/A
5 years (2016-10-20) N/A

Tiziana Life Sciences financials

Operating margin TTM 852.81%
Gross profit TTM $0
Return on assets TTM -73.11%
Return on equity TTM -137.07%
Profit margin 0%
Book value $0.47
Market capitalisation $146.9 million

TTM: trailing 12 months

Shorting Tiziana Life Sciences shares

There are currently 159,868 Tiziana Life Sciences shares held short by investors – that's known as Tiziana Life Sciences's "short interest". This figure is 15.8% down from 189,783 last month.

There are a few different ways that this level of interest in shorting Tiziana Life Sciences shares can be evaluated.

Tiziana Life Sciences's "short interest ratio" (SIR)

Tiziana Life Sciences's "short interest ratio" (SIR) is the quantity of Tiziana Life Sciences shares currently shorted divided by the average quantity of Tiziana Life Sciences shares traded daily (recently around 940400). Tiziana Life Sciences's SIR currently stands at 0.17. In other words for every 100,000 Tiziana Life Sciences shares traded daily on the market, roughly 170 shares are currently held short.

However Tiziana Life Sciences's short interest can also be evaluated against the total number of Tiziana Life Sciences shares, or, against the total number of tradable Tiziana Life Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Tiziana Life Sciences's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Tiziana Life Sciences shares in existence, roughly 0 shares are currently held short) or 0.0046% of the tradable shares (for every 100,000 tradable Tiziana Life Sciences shares, roughly 5 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Tiziana Life Sciences.

Find out more about how you can short Tiziana Life Sciences stock.

Tiziana Life Sciences share dividends

We're not expecting Tiziana Life Sciences to pay a dividend over the next 12 months.

Have Tiziana Life Sciences's shares ever split?

Tiziana Life Sciences's shares were split on a 2499:1000 basis on 30 July 2020. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 2499 shares. This wouldn't directly have changed the overall worth of your Tiziana Life Sciences shares – just the quantity. However, indirectly, the new 60% lower share price could have impacted the market appetite for Tiziana Life Sciences shares which in turn could have impacted Tiziana Life Sciences's share price.

Tiziana Life Sciences share price volatility

Over the last 12 months, Tiziana Life Sciences's shares have ranged in value from as little as $1.36 up to $5.29. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tiziana Life Sciences's is -0.0158. This would suggest that Tiziana Life Sciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Tiziana Life Sciences has bucked the trend.

Tiziana Life Sciences overview

Tiziana Life Sciences plc, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology, inflammation, and infectious diseases. Its lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. The company is also developing Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients. It has a collaboration agreement with FHI Clinical to conduct a Phase 2 clinical trials for treating hospitalized severe COVID-19 patients with intranasal foralumab. The company was incorporated in 1998 and is based in London, the United Kingdom. .

Frequently asked questions

What percentage of Tiziana Life Sciences is owned by institutions?
Currently 14.445% of Tiziana Life Sciences shares are held by institutions.
How many people work for Tiziana Life Sciences?
Latest data suggests 11 work at Tiziana Life Sciences.
When does the fiscal year end for Tiziana Life Sciences?
Tiziana Life Sciences's fiscal year ends in December.
Where is Tiziana Life Sciences based?
Tiziana Life Sciences's address is: 107 Cheapside, London, United Kingdom, EC2V 6DN
What is Tiziana Life Sciences's ISIN number?
Tiziana Life Sciences's international securities identification number is: US88875G1013
What is Tiziana Life Sciences's CUSIP number?
Tiziana Life Sciences's Committee on Uniform Securities Identification Procedures number is: 88875G101

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site